Dahlgren et al. conduct an open-label phase 2 trial of a full-spectrum, high-cannabidiol product in 14 patients with moderate-to-severe anxiety. Anxiety is significantly reduced and the drug well-tolerated with no serious adverse events.
- Mary Kathryn Dahlgren
- Ashley M. Lambros
- Staci A. Gruber
